Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+cells and/or CFU-GM with chemotherapy and G-CSF

BACKGROUND: Mobilization with chemotherapy and G-CSF may result in poor per ipheral blood HPC collection, yielding <2 x 10(6) CD34+ cells per kg or <10 x 10(4) CFU-GM per kg in leukapheresis procedures. The best mobilization s trategy for oncology patients remains unclear. STUDY DESIGN AND METHODS: In 27 patients who met either the CD34 (n = 3) or CFU-GM (n = 2) criteria or both (n = 22), the results obtained with two su ccessive strategies-that is, chemotherapy and G-CSF at 10 mu g per kg (Grou p 1, n = 7) and G-CSF at 10 mu g per kg alone (Group 2, n = 20) used for a second mobilization course-were retrospectively analyzed. The patients had non-Hodgkin's lymphoma (5), Hodgkin's disease (3), multiple myeloma (5), ch ronic myeloid leukemia (1), acute myeloid leukemia (1), breast cancer(6), o r other solid tumors (6). Previous therapy consisted of 10 (1-31) cycles of chemotherapy with additional chlorambucil (n 3), interferon (n = 3), and r adiotherapy (n = 7). RESULTS: The second collection was undertaken a median of 35 days after the first one. In Group 1, the results of the two mobilizations were identical . In Group 2, the number of CD34+ cells per kg per apheresis (0.17 [0.02-0. 45] vs. 0.44 [0.11-0.45], p = 0.00002), as well as the number of CFU-GM (0. 88 [0.00-13.37] vs. 4.19 [0.96-21.61], p = 0.00003), BFU-E (0.83 [0.00-12.7 2] vs. 8.81 [1.38-32.51], p = 0.00001), and CFU-MIX (0.10 [0.00-1.70] vs. 0 .56 [0.00-2.64], p = 0.001134) were significantly higher in the second peri pheral blood HPC collection. However, yields per apheresis during the secon d collection did not significantly differ in the two groups. Six patients i n Group 1 and 18 in Group 2 underwent transplantation, and all but one achi eved engraftment, with a median of 15 versus 12 days to 1,000 neutrophils ( NS), 22 versus 16 days to 1 percent reticulocytes (NS), and 26 versus 26 da ys to 20,000 platelets (NS), respectively. However, platelet engraftment wa s particularly delayed in many patients. CONCLUSION: G-CSF at 10 mu g per kg alone may constitute a Valid alternativ e to chemotherapy and G-CSF to obtain adequate numbers of peripheral blood HPCs in patients who previously failed to achieve mobilization with chemoth erapy and G-CSF. This strategy should be tested in prospective randomized t rials.